One of the biggest challenges in drug discovery is directing drug treatment to the correct population. Crown Bioscience currently has over 1,800 Patient derived xenograft models in >70 indications. These models, HuPrime® human surrogate mouse models, are reflective of the diversity of genetics, tumor heterogeneity and response in patient populations. HuPrime® models are searchable in the HuBase™ database by the expression data, copy number, mutational analysis as well as patient clinical data including diagnosis, pathology and IHC information. The vast number of models available allows one to perform surrogate clinical trials in a Phase II-like trial utilizing one patient sample per tumor bearing animal per treatment group (n = 1 studies). In this study we show reproducibility of n = 1 studies compared to the traditional preclinical mouse studies with multiple animals with the same tumor being treating with the same test agent. Further we show, the use of one patient sample per treatment allows for the expansion of the study utilizing multiple patient samples thereby reducing cost of preclinical studies. One can leverage the HuPrime® models to discover biomarkers, identify patient responder and non-responder profiles to accelerate drug development and improve chances of success in the clinic.

Citation Format: Jayant Thatte, Jill Ricono, Colleen Scott, Thomas B. Broudy. Using HuTrial™ to aid in predicting a patient population of responders. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5186.